This report is not a personal recommendation and does not take into account your personal circumstances or appetite for risk.
The below stocks have been identified as having potential to register bigger than normal share price moves (up or down) today based on the news cited
Kraft Heinz Co (KHC), Unilever (ULVR.L)- Krafts $143bn bid for Unilever, which could have been the largest takeover in the food & beverage industry, collapsed only two days after it became public knowledge, with the adamance of Unilever’s rejection said to play into billionaire Warren Buffett’s longtime aversion to hostile deals. Closing prices 3797.00p $96.65c (Bloomberg)
AstraZeneca PLC (AZN.LN) - Announced a deal giving TerSera Therapeutics LLC commercial rights to its prostate cancer treatment Zoladex in the U.S. and Canada. TerSera will pay AstraZeneca $250m on completion, plus up to $70m depending on sales figures and recurring quarterly sales-based payments. AstraZeneca share price has climbed 2.7% since Thursday's Ex-Dividend date . Closing prices 4595.00p (Bloomberg)
Bovis Homes Group PLC (BVS.L) - Full year revenue rose to £1.05bn against £946.5m previously, however pretax profit was down 3.3%. It announced between 10%-15% fewer homes would be built in 2017 while the dividend for the full year was up 13%. Customer service issues saw a one off £7m provision as well. Closing price 841.00p (Bloomberg / Reuters)
Vedanta Plc (VED.L) - Reports earnings hit $882.3m, a 79% increase from a year earlier on higher commodity prices and production volume; revenue was also up 26% to $3.07bn. Silver output was up 2% though copper production fell 18% y-o-y. Closing price 1040.00p (Bloomberg)
For more information on any of these individual news items, call into the trading floor
This research is produced by Accendo Markets Limited. Research produced and disseminated by Accendo Markets is classified as non-independent research, and is therefore a marketing communication. This investment research has not been prepared in accordance with legal requirements designed to promote its independence and it is not subject to the prohibition on dealing ahead of the dissemination of investment research. This research does not constitute a personal recommendation or offer to enter into a transaction or an investment, and is produced and distributed for information purposes only.
Accendo Markets considers opinions and information contained within the research to be valid when published, and gives no warranty as to the investments referred to in this material. The income from the investments referred to may go down as well as up, and investors may realise losses on investments. The past performance of a particular investment is not necessarily a guide to its future performance. Prepared by Michael van Dulken, Head of Research